What it sells
We create activating antibodies to treat diseases others can’t.
Business model breakdown
Workflow: what inputs become what output?
Function-first antibody discovery: screen for antibodies that activate hard-to-drug targets rather than only bind or inhibit.
Economics: what it saves and how it charges
UnverifiedDrug-discovery biotech; value comes from pipeline assets and partnerships (Partnerships page) rather than product sales.
Distribution: how it reaches customers
UnverifiedPharma partnerships and licensing.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.